Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100563 | 0.88 | CHRNB2 (0.33) | HCRTR1SSTR4SSTR1IRAK4 | |
| SCHEMBL6100540 | 0.84 | HCRTR1 (0.33) | HCRTR1IRAK4 | |
| SCHEMBL6099923 | 0.84 | CHRNB2 (0.34) | — | |
| SCHEMBL6096789 | 0.81 | HCRTR1 (0.34) | HCRTR1 | |
| SCHEMBL6099932 | 0.81 | CNR2 (0.33) | SSTR4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6098300 | 0.80 | HCRTR1 (0.33) | HCRTR1SSTR4SSTR1TAS1R3TAS1R1 | |
| SCHEMBL6100927 | 0.80 | CHRNB2 (0.35) | HCRTR1 | |
| SCHEMBL6097489 | 0.80 | HCRTR1 (0.30) | HCRTR1 | |
| SCHEMBL6101327 | 0.80 | CHRNB2 (0.34) | — | |
| SCHEMBL6098610 | 0.78 | TAS1R3 (0.35) | HCRTR1SSTR4TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HCRTR1 1335/4885SSTR4 828/4885SSTR1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.